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Abstract: With an annual incidence of 1–2 in a million, Ph*(+) chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell
disease that makes myeloid neoplastic cells breed out of control. This BCR-ABL(+) myeloproliferative disease makes up about 15%–20%
of all leukemia cases in adults. CML is seen more in males than females, with a rate of three to two. However, it does not show differences
in prevalence in terms of age. CML consists of three clinical phases. The first one is the chronic phase, defined by rising white blood cell
levels and also by myeloid proliferation and bone marrow maturation. While this phase does not exhibit complications, in diagnosis,
it comprises most of the patients. The second phase is the accelerated phase, which the disease progresses to if it is not treated or does
not respond to treatment. This usually takes about 3 years. The third phase is the blastic phase. The chronic phase can still progress
to the next two phases within the first 2 years, with a rate of 10%. In the following years, the possibility increases by 15%–20% each
year. Tyrosine kinase inhibitors (TKIs) are revolutionary drugs for the management of disease course in CML. The aim of this review
is to assess current approaches to CML patients’ follow-up and treatment with TKIs. A literature search on CML and TKIs was made
in PubMed, Web of Science, and Scopus with particular focus on randomized clinical trials, recommendations, guidelines, and expert
opinions. In managing CML, various treatment methods have been utilized for many decades. Prior to the development of TKIs,
interferon alpha was the primary tool, which was then complemented by allogeneic hematopoietic stem cell transplantation (HSCT).
HSCT was successful in slowing the disease down in the long term and curing up to 50% of patients. Then the coming of the imatinib
era opened up different treatment perspectives. For the patients resistant or intolerant to imatinib, second- and third-generation TKIs
are successfully used in distinct CML disease states. The survival benefits of TKIs including imatinib, nilotinib, dasatinib, bosutinib, and
ponatinib for CML patients are outstanding. TKI-related adverse events could impact the clinical course, especially in long-term drug
administrations. The current aim for CML disease management in the TKI era is to provide age- and sex-matched normal life duration
to CML patients.
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1. Introduction
Defined by the spreading of myeloid neoplastic cells
in the circulating blood and in the bone marrow,
chronic myeloid leukemia (CML) is a malignant clonal
hematological disease. The existence of the Philadelphia
(Ph) chromosome causes the fusion transcript BCR-ABL
to form. The pathological activity of BCR-ABL leads
to myeloid neoplasia as well as genomic instability [1].
Medications that inhibit BCR-ABL formation, called
tyrosine kinase inhibitors (TKIs), are helpful in restoring
normal hematopoiesis and providing hematological,
cytogenetic, and molecular alleviation. These medications
can also facilitate this with accurate monitoring of patients
[2]. If the inhibitors fail in limiting the BCR-ABL, the
disease potentially progresses on to the accelerated phase
or the blastic phase. This progression leads to death in
3 years [3]. As is the case with various chronic benign

diseases, like diabetes and hypertension, rationally
administrating these inhibitors can be related to normal
age- and sex-expected life duration [4]. In this review, we
intend to summarize the existing TKI treatment methods
in CML along with future treatment aspects.
2. The definition, classification, and scoring of CML
CML was defined as the discovery of t(9;22) (q34.1;q11.2)
by traditional cytogenetics along with the discovery of
BCR-ABL1 by molecular genetic practices by the World
Health Organization in its revision of myeloid neoplasm
classification in 2016. This classification also included
complete karyotype and bone marrow morphologic
findings to verify the myeloid disease. The revision
describes the accelerated phase of CML depending on the
morphologic, hematological, and cytogenetic parameters.
These parameters are completed by genetic evolution and
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12 months
with imatinib
Major critical conclusion
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Table 1. Main studies comparing different imatinib doses used in CML treatment.

3. Frontline treatment of CML
Using TKIs orally is quite common for CML patients
in the present period. Imatinib mesylate at 400 mg/day
is common as the frontline treatment, whereas some
extraordinary cases may require dasatinib at 100 mg/day
or nilotinib at 600 mg/day [7–10]. There are inhibitors
available that are more powerful than these, although they
should be reserved for patients with risky Sokal scores or
complex karyotypic anomalies. Determining the risk score
is key for newly diagnosed patients. For frontline treatment,
the following should be taken into consideration: patients’
comorbidities, preferences, individual characteristics, drug
toxicity profiles, and physician experiences [8,10–12].
3.1. Imatinib mesylate as frontline treatment
From previous studies on the ideal dose of imatinib to
be used for CML patients, the frontline treatment is
recommended as imatinib mesylate at 400 mg/day. Table
1 shows the comparison of inhibitor doses in those studies.
Kantarjian et al. suggested 800 mg/day imatinib to be
more efficient than 600 mg/day for frontline treatment.
While the high-dose imatinib group of that study
exhibited complete cytogenetic response (CCyR) by 90%
and major molecular response (MMR) by 63%, side effects
such as hematotoxicity, hepatotoxicity, and skin rash were
also seen in the same group [13]. In a study that applied
800 mg/day imatinib mesylate as the frontline treatment
in patients with risky Sokal scores, the rates observed at
12 months and 24 months were as follows: CCyR at 88%
and 91% and MMR at 56% and 73%, respectively. The
rates of side effects were even higher than those found
by Kantarjian et al., this time including myalgia, nausea/
vomiting, and diarrhea [14].
Hughes et al. compared 600 mg/day imatinib mesylate
with 800 mg/day and found the response rates for the
800 mg/day group at 12 months and 24 months to be as
follows: CCyR at 88% and 90% and MMR at 47% and 73%,
respectively [15].

MMR
12 months
with imatinib

TKI resistances. They describe the blastic phase based on
the occurrence of at least 20% blasts in the circulating blood
or bone marrow or on extramedullary accumulation being
observed in blastic cells [5]. There are other cytogenetic
anomalies (Iso(17q), additional Ph, +19, -7, 3q26, +8) that
can cause complications in CML [6].
In composing long-term treatment plans for TKI-naïve
patients, prognostic evaluation of CML is key [4]. Prior to
the use of inhibitors, Sokal CML scoring was a widely used
system. It is based on the age, spleen, blasts, and platelets
of the patient. Similarly, another system of the same era,
Euro-Hasford, takes the same into account in patients,
with the addition of eosinophils and basophils. The single
system used in the era of TKIs is EUTOS, which is based
only on spleen and basophils. However, the long-term
survival evaluation of EUTOS adds age and blasts [4].
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Deininger et al. did the same with an 800 mg/day group
compared to a group receiving the standard dose (400 mg/
day). Their findings showed CCyR by 85% in the 800 mg/
day group at 12 months and by 67% in the 400 mg/day
group, while at 12 months MMR was seen by 53% and 35%
in the 800 mg/day and 400 mg/day groups, respectively
[16].
Other than studies that support higher doses of
imatinib mesylate to be more efficient, there are also
studies that support higher doses of imatinib to be more
effective, such as the American TKI Optimization and
Selectivity (TOPS) study, the Central European Imatinib
Standard, or the ELN vs. High Dose Imatinib Trial study.
In the TOPS study, where 400 mg/day or 800 mg/
day imatinib mesylate was given randomly to patients
as frontline treatment, 12-month response rates were
observed as follows: CCyR at 70% and 66% and MMR
at 46% and 44% in the 800 mg/day group and the 400
mg/day group, respectively. These differences were not
significant, along with the progression of disease. However,
hematological and nonhematological side effects were
seen more in the 800 mg/day group [17].
Baccarani et al. studied the same dose groups as
the TOPS study in their ELN study, although they only
studied patients with risky Sokal scores. As was the case
with the TOPS study, they did not have findings supporting
higher doses of imatinib. The 12-month response rates
were observed as follows: CCyR at 64% and 58% and
MMR at 40% and 33% in the 800 mg/day group and the
400 mg/day group, respectively [18].
The Central European Leukemia Group
conducted their study by applying 400 mg/day imatinib
after 800 mg/day application to CML patients as the
frontline treatment, and CCyR rates were significantly
worse whereas MMR rates were seen to be higher at 6
months in the group receiving the higher dose [19].
Organic cation transporter 1 (OCT1) is defined as an
influx transporter facilitating imatinib transportation to
CML cells. Hughes et al. reported evident differences in
MMR rates and survival rates between patients who were
given 600 mg/day imatinib with high OCT1 activity and
low OCT1 activity [20]. The study suggests that OCT1
activity acts as a determinative factor for MMR and
progression-free survival rates in patients where imatinib
is used as the frontline treatment. It can also be helpful
in detecting patients requiring higher doses of imatinib in
frontline treatment [20].
3.2. Second-generation TKIs in frontline treatment
Second-generation TKIs, dasatinib and nilotinib, show
stronger response and tolerability compared to imatinib,
making them more suggestible as frontline treatment
for patients with risky Sokal scores. There have been
two studies on the comparison between these secondgeneration TKIs and imatinib in patients with CML.

In the ENESTnd study, with groups receiving 400–
300 mg nilotinib twice a day and a 400 mg/day imatinib
mesylate group, statistically significant differences were
observed. The nilotinib groups exhibited higher MMR
and CCyR rates at 24 months. The response rates were as
follows: CCyR and MMR were respectively at 87% and 71%
in the 300 mg nilotinib group, 85% and 67% in the 400 mg
nilotinib group, and 77% and 44% in the imatinib group
[10]. Similarly, the DASISION study was conducted with
a 100 mg/day dasatinib group and a 400 mg/day imatinib
group. The 24-month response rates were as follows: CCyR
at 86% and 82% and MMR at 64% and 46% in the dasatinib
group and the imatinib group, respectively. As these two
studies have shown, these second-generation TKIs show
better response rates as frontline treatment methods in
patients with CML.
The NiloPeg study was conducted with patients with
CML in the chronic phase, where nilotinib at 300 mg twice
a day was given to patients along with Peg-IFN for 1–2
years, and they were only given nilotinib past the 2-year
mark. The combination period’s CCyR rates at 6 and 12
months were 71% and 100%, respectively, while the MMR
rates at 12, 24, 36, and 48 months were 76%, 78%, 83%, and
73%, respectively [21]. A similar study, PETALS, compared
a 600 mg/day nilotinib group with a 600 mg/day nilotinib
+ Peg-IFN group in de novo Philadelphia-positive patients
with CML in the chronic phase. The collection of findings
in these studies showed that nilotinib combined with PegIFN is an applicable and efficient method for better, earlier,
and deeper MMR [21,22].
3.3. Which TKI is the best method as the frontline
treatment of CML patients?
There are a number of treatment methods that can be
considered for CML patients thanks to the new studies
conducted.
Method 1: As the frontline treatment, 400 mg of
imatinib is safe to be prescribed to any patient, which
should be followed by a second-generation TKI in the case
of resistance or intolerance. So far, there is no determinative
difference in the choice of a second-generation TKI, so any
one of the medications with a positive pharmacoeconomic
characteristic is safe to be prescribed.
Method 2: Based on the Sokal scores of patients, 400 mg
of imatinib or a second-generation TKI can be prescribed
for low or high risk scores, respectively.
Method 3: Any one of the second generation TKIs or
imatinib may be prescribed as the frontline treatment.
Imatinib treatment can have some side effects, of which
the most widely observed one is swelling in periorbital and
lower extremities. It is observed with high frequency in
patients older than 65 years and in patients who are given
high doses. While the side effects can mostly be alleviated
with diuretics, prescribing one of the second-generation
TKIs may still prove safer as the frontline treatment [23,24].
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Another side effect of imatinib treatment is the occurrence
of bone marrow suppression, mostly appearing during the
first few months of therapy. In addition, hypothyroidism
is seen, at 2 weeks on average, in patients who receive
thyroid hormone treatment before taking imatinib, where
levothyroxine doses may be doubled [25].
As dasatinib can lead to fluid retention along with
pleural effusion and pericardial effusion, in patients with
pleural effusion or with a high risk of pleural effusion
occurrence, prescribing another inhibitor would be
better. Dasatinib may also lead to pulmonary arterial
hypertension, in the treatment of which stopping dasatinib
induction can help improve hemodynamic parameters,
as vasodilator agents do not exhibit clinical advantages
[26,27]. For the side effect of bone marrow suppression,
which occurs due to dasatinib induction, particularly
in advanced cases of CML, adjusting the doses can help
reverse the side effect. Another side effect observed due to
dasatinib induction is platelet dysfunction [10,28].
The other second-generation TKI, nilotinib, may
deteriorate glucose levels in blood, which is not a case
seen with the two other inhibitors. Another side effect of
nilotinib is QT interval prolongation, which is not seen
frequently but is lethal, so it should be monitored at the
beginning of the treatment and throughout the whole
process [10,29]. Nilotinib is also stated to be related to

DATA ON
THE SAFETY,
EFFICAC Y,
TOLERABILITY,
TOXICITY,
RANDOMIZED
CLINICAL
TRIALS, LONG
TERM
FOLLOW -UP
DATA

cardiovascular disorders, which were observed to increase
in occurrence with induction by nilotinib (8% for nilotinib
300 mg, 13% for nilotinib 400 mg, 2% for imatinib),
suggesting that imatinib is better in patients with severe
cardiovascular diseases [30] (Figure 1).
3.4. Tracing TKI response in CML
After TKI treatment in the first phase for CML patients,
certain evaluations are required. The tests needed for these
evaluations are as follows: full blood count and peripheral
blood smear (to evaluate hematological response), physical
examination, cytogenetic analysis (to evaluate cytogenetic
response), and quantitative Bcl-Abl1 analysis (to evaluate
molecular response).
The cytogenetic assessment needs to be started as soon
as the patient is diagnosed and needs to be repeated at the
3rd and 6th months. Then the assessment needs to be done
once every 6 months for as long as CCyR is not observed.
Similarly, molecular monitoring needs to be continued
once every 3 months as long as MMR is not verified.
After verifying the response, the assessment needs to be
repeated once every 3–6 months. This test needs to be done
with RT-QPCR, which may be an approved and helpful
assessment tool but has the possibility of demonstrating
different findings in each laboratory or even in the same
laboratory (Table 2).

CML DISEASE
RISK, AGE,
COMORBIDITIES ,
MOLECULAR
PATIENT
PROFILE,
CHARACTERISTICS COMPLIANCE,
LIFE STYLE,
DRUG OFFTARGET RISK
PROFILE, LIFE
PHYSICIAN
EXPECTANCY

EVIDENCE

AND
CLINICS

TKI
AVAILABILITY,
TKI
REIMBURSABILITY,
DRUG
EXPERIENCE,
ADHERENCE,
MONITORIZ ATI
ON FACILITY
Figure 1. Clinical decision making for any tyrosine kinase inhibitor (TKI) drug in chronic myeloid leukemia (CML). Clinical decision
should be reached based on the optimization of the best available evidence, individual patient/disease characteristics, and clinical experience.
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Table 2. Response evaluation with first-line therapy (ELN 2013).
Optimal response

Warning

Baseline

--

High Sokal risk/Hasford score

3 months

BCR-ABLIS ≤10%
Ph+ ≤35% (PCyR)

BCR-ABLIS >10%
Ph+ 36-95%

No CHR
Ph+ >95%

6 months

BCR-ABLIS <1%
Ph+ 0% (CCyR)

BCR-ABLIS 1-10%
Ph+ 1-35%

BCR-ABLIS >10%
Ph+ >35%

12 months

BCR-ABLIS ≤0.1% (MMR) BCR-ABLIS 0.1%–1%*

Any time

MMR or better

CCA/Ph- (-7 or 7q-)

BCR-ABL1 levels in patients under TKI treatments
have been observed as determinative parameters, where
BCR-ABL1 levels above 10% at the 3rd month are a
negative determinative factor for the patient. There have
been studies demonstrating this with various TKIs, such
as GIMEMA and German CML IV (imatinib), DASISION
(dasatinib), and ENESTnd (nilotinib) [10,11,31,32]. It
was also stressed in the ELN 2013 recommendations
that patients with BCR-ABL1 levels above 10% after
the 3rd month are at critical risk and close monitoring
is needed until the 6th month. For patients showing no
complete hematological response and/or cytogenetic
response, switching to another inhibitor might prove
helpful, where imatinib should be dropped for one of the
second-generation TKIs or its dose should be increased.
If the patient was already being given one of the secondgeneration TKIs, switching to another one might prove
helpful [18]. The recommendations state that better and
quicker response rates have been seen in changing to
the second-generation TKIs, though long-term survival
benefits are still to be reported.
The recommendations further suggest that observing
BCR-ABL1 levels under 1% after the 6th month or under
0.1% after the 12th month shows the ideal response
desired, whereas if BCR-ABL1 levels stay above 10% and/
or Ph chromosome is observed to be above 35% at the
6th month it means a failure in treatment, requiring a
modification in the treatment method.
Dasatinib and nilotinib have been observed to be better
at preventing the progression of CML. The key factors in
the treatment of the disease are efficiently managing both
the side effects of the inhibitors and the increased costs
[7,8].

Failure

BCR-ABLIS >1%*
Ph+ >0%
Loss of CHR
Loss of CCyR
Loss of MMR
Confirmed loss of
MMR
Mutations
CCA/Ph+

4. Second-line TKI treatment for CML
With all the benefits of TKIs, one problem with using
them in treatment is, as mentioned before in this paper,
patients developing a resistance to the drugs. Other than
resistance, intolerance, less-than-optimal response, and
relapse following first response are also existing problems.
If a patient develops a resistance to imatinib, the treatment
can be continued with one of the second-generation TKIs
thanks to the lack of cross-intolerance.
As stated above, patients with BCR-ABL1 levels above
10% or Ph levels above 65% at the 3rd month are in a
warning stage where replacing imatinib with one of the
second-generation TKIs may prove useful, even though
there is no information regarding long-term survival
effect. For patients with BCR-ABL1 levels below 10% at the
3rd month or below 1% at the 12th month, continuance
of the treatment is up to the clinician based on adherence
problems, the rate of BCR-ABL1 decline, and the closeness
to the critical levels of BCR-ABL1 depending on the
time since the treatment started. Failure to achieve the
aforementioned levels of BCR-ABL1 within the first
3 months puts patients in a risky position regarding
progression of disease, but they can still keep using the
same dose of the inhibitor for the next 3 months. For these
patients, the necessary considerations in the following
period would be mutational examination, allogeneic HCT
assessment, and bone marrow cytogenetics evaluation
(3rd month for MCyR/12th month for CCyR).
Patients with BCR-ABL1 levels above 10% at and
after the 6th month and above 1% at the 15th month are
considered resistant to the inhibitors. For these patients,
HCT assessment is suggested (at the discretion of a
transplant specialist, with the possibility of an HLA test
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being required) and alternative treatment methods need
to be considered, which will be discussed further in the
following sections.
5. Third-line treatment for CML
With the failure of second-line treatment as in the
mentioned response rates given above, proceeding
to third-generation TKIs and/or allogeneic stem cell
transplantation (allo-SCT) is authorized. In order to
detect the occurrence of a BCR-ABL1 domain mutation
in CML cells and whether the patients have moved on to
the third phase (blastic phase), bone marrow biopsy needs
to be done. Evaluating the second-generation TKIs and
bosutinib and ponatinib in addition to them, along with
the observed mutation, should demonstrate which drug
would be useful in the following phase.
With a toxicity profile unlike any other inhibitor,
bosutinib is a possible choice for patients not responding
to dasatinib and nilotinib. Limiting its use is only one side
effect, which is diarrhea, leading to myelosuppression and
hepatotoxicity [33].
Bosutinib is not effective in T315I mutations, as with
the second-generation TKIs, where the only remaining
option will be ponatinib. If the desired response rates are
still not observed after the induction of ponatinib, alloSCT needs to be performed in the event that a donor is
present. Ponatinib has very low side effect occurrence at
15–30 mg/day, with vaso-occlusive disease, skin rashes,
and thromboembolism being seen in rare occasions [34].
6. Withdrawal of TKIs in CML
Among other studies on the effects of stopping TKI
treatment, EURO_SKI stands out for having the largest
population, where 821 CML patients who were treated
with imatinib, dasatinib, or nilotinib as first-line treatment
had the drugs discontinued and the survival rate without
relapse was 52% at 2 years after discontinuance. Following
the withdrawal of the drugs, 86% of the patients in the
study stopped showing MMR, and 81% of the patients
started showing response again after starting reuse of the
drug. The study proposed that stopping TKIs would be
safe as long as close monitoring is available [35].
In another study (STIM), patients using imatinib for 2
years and showing MMR had the medication discontinued
and 61% of them showed deterioration at the 6th month
following withdrawal. The same percentage of patients
started showing response following the restarting of the
drug, with decreases in BCR-ABL1 levels being observed
in some others [36]. In the TWISTER study, 42% of
40 patients showed survival without any deterioration
following the 2 years after withdrawal. In that study,
every patient demonstrated response after the drug was

6

restarted, showing that the alleviations and deteriorations
observed were changing in each study [37].
Another study (ENEST) discontinued nilotinib in
patients following a year of response, where 51.6% of them
kept showing response for 2 more years, and resuming the
drug showed responses in the majority of the rest [38].
For young or pregnant patients or those for whom
treatment needs to be stopped after a period of time, using
the second-generation inhibitors as frontline treatment
would prove better, as we know so far that these drugs
demonstrate longer response times following withdrawal
[39].
Molecular cure levels are quite low in patients
receiving inhibitor treatments. Various studies try to
achieve CML stem cell control or resistant leukemic cell
disposal. In patients with lower and medium levels of
CML risk, imatinib and dasatinib are the two drugs that
lead to better MMR along with Peg-IFN [40,41]. There is
also information regarding increased apoptosis rates along
with venetoclax and other some inhibitors in patients
receiving imatinib, although wider population studies
need to be conducted to obtain proof for clinical use [42].
7. Managing the blastic phase in CML
Prior to the TKI era, the blastic phase was unavoidable for
CML patients, even though the inhibitors somehow led
to increases in the time duration of the first phase. Today,
occurrence of the blastic phase is about 1% annually, for
which the suggested treatment objective is to either push
the disease progression back into the chronic phase or to
provide alleviation for the patient (Figure 2).
In patients progressing on to the second or third stage,
suggested methods include the use of dasatinib or ponatinib,
which can be coupled with chemotherapy to increase the
chances of survival and response. Considering the blastic
phase in two types, as myeloid and lymphoid, suggested
treatments are anthracyclines and cytosine arabinoside for
the former and vincristine and prednisolone for the latter.
The only known curing treatment method is allo-SCT
(10% to 40% cure rate), if a donor is available, and further
TKI use afterwards has showed decreased deterioration
and DLI need. A study conducted with 477 CML patients
in the third phase demonstrated that coupling TKI
treatment, chemotherapy, and allo-SCT yielded the most
successful results by 46%. In patients who start directly in
the second phase (accelerated phase) and received TKIs,
survival rates are between 60% and 80%, higher than the
rates of patients progressing on to this stage following the
chronic phase.
For patients who do not respond to the inhibitors and
worsen throughout the application of ideal treatment
methods, close monitoring is suggested, as these patients
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Figure 2. Histopathological demonstration of the myeloid expansion in chronic phase CML (upper panels), resulting in the
advanced blastic crisis of CML (lower panels) with failure of tyrosine kinase inhibitors (courtesy of Professor Ayşegül Üner, MD,
from Hacettepe University Medical School, Ankara, Turkey).

are to be considered highly risky for progression on to the
third stage, knowing that there is yet to be an ideal method
in managing this phase.
8. Future aspects and suggestions for CML
The subjects of new studies on CML patients include the
effectiveness of methods like gene expression profiling,
next-gen genomics, genetic polymorphisms, multidrug
resistance genes, and existing BCR-ABL kinase domain

mutations [43]. Future studies should aim to ensure
reliable MMR rates and enable continuity for patients
without the need for keeping up treatment. Apart from
the tests, regarding coupling the TKIs with certain other
agents (cl-2 inhibitors, protein synthesis inhibitors, or PegIFN) that were referred to multiple times in this paper,
other combinations of the existing methods of treatments,
or possibly discoveries of new agents, may ultimately aid in
finding a cure for CML.
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